Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety and PK/PD

NCT02285101 is registered in ClinicalTrials.gov with Bio-Cancer Treatment International Limited as lead sponsor.

NCT NCT02285101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02285101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety and PK/PD
Lead sponsor
Bio-Cancer Treatment International Limited
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2014
Completion date
February 28, 2019
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, prostate adenocarcinoma